Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
3.800
+0.130 (3.54%)
Jul 2, 2026, 4:00 PM EDT - Market closed

Recursion Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
2,0172,1602,6822,3101,4732,917
Market Cap Growth
2.41%-19.46%16.13%56.84%-49.51%-
Enterprise Value
1,4351,4952,1971,969973.882,401
Last Close Price
3.804.096.769.867.7117.13
PS Ratio
30.3728.9345.5951.8236.96286.58
PB Ratio
1.971.912.594.983.035.37
P/TBV Ratio
3.202.783.375.472.803.97
EV/Sales Ratio
21.6120.0237.3344.1724.44235.89
Debt / Equity Ratio
0.060.060.090.100.090.00
Net Debt / Equity Ratio
-0.57-0.59-0.47-0.74-1.03-0.95
Net Debt / EBITDA Ratio
1.001.181.101.052.132.96
Net Debt / FCF Ratio
1.811.761.301.144.142.60
Asset Turnover
0.050.050.060.070.060.02
Quick Ratio
5.155.203.434.245.5111.27
Current Ratio
5.475.503.814.705.6811.46
Return on Equity (ROE)
-51.94%-59.54%-61.90%-69.12%-46.56%-47.51%
Return on Assets (ROA)
-41.26%-44.34%-45.46%-51.04%-37.47%-40.22%
Return on Invested Capital (ROIC)
-127.84%-127.75%-142.33%-631.89%-3510.89%-1876.25%
Return on Capital Employed (ROCE)
-46.15%-50.10%-52.59%-60.27%-42.20%-43.56%
Buyback Yield / Dilution
-51.66%-63.18%-31.92%-18.41%-40.04%-475.48%
Total Shareholder Return
-51.66%-63.18%-31.92%-18.41%-40.04%-475.48%
SEC Filings: 10-K · 10-Q